At a glance
| US product | Aphexda |
|---|---|
| Target | CXCR4 |
| Required partner | Filgrastim / G-CSF |
| Approved purpose | Stem-cell collection before autologous transplant in multiple myeloma |
| Important risk | Anaphylactic shock and hypersensitivity |
Overview
Autologous stem-cell transplantation requires collection of enough of a patient’s own hematopoietic stem cells before high-dose therapy. Motixafortide helps release those cells from the bone-marrow environment when used with granulocyte colony-stimulating factor, marketed as filgrastim. The US product Aphexda is approved for this mobilization purpose in multiple myeloma. Clinical outcomes in the pivotal program concerned successful cell collection within a limited number of apheresis procedures. They should not be described as proof that motixafortide directly treats myeloma or prolongs survival. Other oncology combinations involving the same pathway remain separate research questions with different endpoints and risk considerations.
How it works
Motixafortide binds CXCR4 and inhibits its interaction with CXCL12, a chemokine signal that helps retain hematopoietic stem cells within marrow niches. Disrupting this signal increases circulating CD34-positive cells available for apheresis. CXCR4 also participates in other immune and tumor-cell processes, but that broad biology does not extend the approved indication automatically. Mobilizing malignant cells is one reason the intended transplant context matters.
Helping collect cells for transplantation
The labeled use combines motixafortide with filgrastim to mobilize hematopoietic stem cells into peripheral blood for collection and subsequent autologous transplantation. This is a preparatory treatment within a transplant program. It is not an approved stand-alone anticancer therapy or a general method of stimulating regeneration in healthy people.
Supporting sources [1]
What GENESIS demonstrated
The randomized GENESIS trial compared motixafortide plus G-CSF with placebo plus G-CSF. A much larger proportion of treated participants collected the prespecified CD34-positive cell target within two apheresis procedures. This directly supports mobilization efficacy, but it does not independently establish longer survival or superior cancer control after transplantation.
Hypersensitivity and cell-mobilization concerns
The label warns about anaphylactic shock, hypersensitivity, injection-site reactions, leukocytosis, and potential mobilization of tumor cells. It specifically cautions against use for mobilization in leukemia because leukemic cells may enter circulation. Premedication and observation are part of the approved administration framework rather than evidence that reactions cannot occur.
Supporting sources [1]
Does CXCR4 blockade make it an approved cancer immunotherapy?
No. A molecular target can support several development programs, but each needs its own outcomes and authorization. Aphexda’s approval is tied to stem-cell collection in multiple myeloma. Experimental tumor-microenvironment studies and combinations cannot be presented as additional approved indications.
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Cyclic peptide CXCR4 antagonist; hematopoietic stem-cell mobilizer.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Aphexda — US prescribing information ↗Regulatory source · Checked 2026-10-27
- Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. ↗Original research · Checked 2026-10-27